CMS updates Hospital Compare, seeks quality measures feedback

CMS is undergoing a revamp of its Compare websites, which allow patients and users to compare healthcare providers based on quality measures. The agency recently updated its Hospital Compare website with new measurement data and the Overall Hospital Quality Star Ratings.

CMS also recently announced it was planning to overhaul all the Medicare comparison tools into one combined portal that is easy to use and simple to navigate.

The agency announced last year it was planning to update the quality measurements of Hospital Compare, which would be reflected in the star ratings that rate hospitals on quality, with five stars being the best. The updated star ratings issued this week “use the existing methodology to ensure patients have the information they need,” CMS Administrator Seema Verma wrote in a blog post Jan. 29.

The agency asked for feedback on how to update the star ratings methodology via national quality conferences, listening sessions and soliciting advice from experts. The information received will inform methodology proposals planned to be issued in spring 2020 for the fiscal year 2021 Hospital Inpatient Prospective Payment System proposed rule.

Verma also noted the agency is still seeking feedback on the upcoming proposals and start ratings methodology.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.